StockNews.com Lowers Chimerix (NASDAQ:CMRX) to Sell

StockNews.com cut shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a report released on Friday.

CMRX has been the topic of several other reports. Wedbush restated an outperform rating and issued a $6.00 price objective on shares of Chimerix in a report on Monday, February 12th. HC Wainwright reaffirmed a buy rating and issued a $11.00 price objective on shares of Chimerix in a research note on Friday, March 1st.

Chimerix Stock Performance

Shares of NASDAQ CMRX opened at $1.00 on Friday. The firm has a fifty day moving average of $1.04 and a 200 day moving average of $1.00. Chimerix has a one year low of $0.88 and a one year high of $1.57. The firm has a market cap of $89.63 million, a PE ratio of -1.08 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same quarter in the previous year, the business posted ($0.24) EPS. On average, equities analysts predict that Chimerix will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Chimerix

Several institutional investors have recently modified their holdings of the business. Vance Wealth Inc. acquired a new position in Chimerix in the fourth quarter valued at $46,000. Pale Fire Capital SE purchased a new stake in Chimerix in the 3rd quarter valued at approximately $95,000. Assenagon Asset Management S.A. lifted its holdings in Chimerix by 167.3% in the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 267,044 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Chimerix by 190.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares during the period. Finally, Vestal Point Capital LP purchased a new position in shares of Chimerix in the fourth quarter valued at $1,348,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.